Oculis Holding AG OCS
NASDAQ OCS
$12.17 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Oculis Holding AG (OCS) Restructuring Costs (2023)

Oculis Holding AG (OCS) posted quarterly Restructuring Costs of -$71325.6 for Q3 2023, up 97.33% quarter-over-quarter from -$2.7 million in Q2 2023.

Analysis

Oculis Holding AG (OCS) Restructuring Costs (2023) Analysis & Trends

Oculis Holding AG's Restructuring Costs history runs 1 years deep, the most recent figure standing at -$71325.6 for Q3 2023.

  • In Q3 2023, Restructuring Costs changed N/A year-over-year to -$71325.6; the TTM figure through Dec 2023 stood at -$5.1 million (changed N/A YoY), while the FY2023 annual figure was -$5.1 million, down 2186.62% from the prior year.
  • Restructuring Costs for Q3 2023 stood at -$71325.6, up from -$2.7 million in the prior quarter.
  • The five-year high for Restructuring Costs was -$71325.6 in Q3 2023, with the low at -$2.7 million in Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Oculis Holding AG 634.75 Mn 345.87 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 -71,325.61
Jun 30, 2023 -2.67 Mn
Mar 31, 2023 -2.31 Mn